Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

被引：0
|
作者：
Deborah JL Wong
Lidia Robert
Mohammad S Atefi
Amanda Lassen
Geetha Avarappatt
Michael Cerniglia
Earl Avramis
Jennifer Tsoi
David Foulad
Thomas G Graeber
Begonya Comin-Anduix
Ahmed Samatar
Roger S Lo
Antoni Ribas
机构：
[1] University of California Los Angeles (UCLA),Department of Medicine, Division of Hematology
[2] UCLA,Oncology
[3] UCLA,Department of Molecular and Medical Pharmacology
[4] Jonsson Comprehensive Cancer Center at UCLA,Department of Surgery, Division of Surgical
[5] Discovery Oncology Merck Research Laboratories,Oncology
[6] Merck Research Laboratories,Department of Medicine, Division of Dermatology
[7] UCLA,undefined
[8] University of Applied Sciences,undefined
[9] Universitat Autonoma de Barcelona,undefined
[10] UAB,undefined
来源：
Molecular Cancer | / 14卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature
    Lengyel, Krisztina
    Young, Fergus
    Kucukmetin, Ali
    Cresti, Nicola
    Plummer, Ruth
    Ralte, Angela
    O'Donnell, Rachel Louise
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2020, 39 (04) : 321 - 326
  • [42] ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
    Ryan, Meagan B.
    Finn, Alexander J.
    Pedone, Katherine H.
    Thomas, Nancy E.
    Der, Channing J.
    Cox, Adrienne D.
    MOLECULAR CANCER RESEARCH, 2016, 14 (10) : 1009 - 1018
  • [43] Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors
    Futter, M.
    Diekmann, H.
    Schoenmakers, E.
    Sadiq, O.
    Chatterjee, K.
    Rubinsztein, D. C.
    JOURNAL OF MEDICAL GENETICS, 2009, 46 (07) : 438 - 446
  • [44] DNA binding distinguishes wild-type and mutant p53 activity
    Ray, Debolina
    Gal, Susannah
    CANCER RESEARCH, 2010, 70
  • [45] Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
    Algazi, Alain P.
    Esteve-Puig, Rosaura
    Nosrati, Adi
    Hinds, Brian
    Hobbs-Muthukumar, Adele
    Nandoskar, Prachi
    Ortiz-Urda, Susana
    Chapman, Paul B.
    Daud, Adil
    PIGMENT CELL & MELANOMA RESEARCH, 2018, 31 (01) : 110 - 114
  • [46] SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant
    Tsavachidou, D
    Coleman, ML
    Athanasiadis, G
    Li, SX
    Licht, JD
    Olson, MF
    Weber, BL
    CANCER RESEARCH, 2004, 64 (16) : 5556 - 5559
  • [47] Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase IIα
    Renodon-Cornière, A
    Sorensen, TK
    Jensen, PB
    Nitiss, JL
    Sokilde, B
    Sehested, M
    Jensen, LH
    MOLECULAR PHARMACOLOGY, 2003, 63 (05) : 1159 - 1168
  • [48] Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein
    Orgad, S
    Goldfinger, N
    Cohen, G
    Rotter, V
    Solomon, B
    FEBS LETTERS, 2005, 579 (25) : 5609 - 5615
  • [49] COMPETITIVENESS OF A NIF- BRADYRHIZOBIUM-JAPONICUM MUTANT AGAINST THE WILD-TYPE STRAIN
    HAHN, M
    STUDER, D
    FEMS MICROBIOLOGY LETTERS, 1986, 33 (01) : 143 - 148
  • [50] Fluoroquinolone and Quinazolinedione Activities against Wild-Type and Gyrase Mutant Strains of Mycobacterium smegmatis
    Malik, Muhammad
    Marks, Kevin R.
    Mustaev, Arkady
    Zhao, Xilin
    Chavda, Kalyan
    Kerns, Robert J.
    Drlica, Karl
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 2335 - 2343
12345